Technologies to Advance Next Generation Anthrax Vaccines

通过该奖项可能涉及的产品开发活动范围涵盖通过临床研究的生产和配方工艺开发，包括：cGMP中试批材料的生产、表征和发布；疫苗稳定性试验；进行非临床研究，例如新药研究（IND）毒理学研究；开发、确认并在必要时验证支持产品开发所需的所有分析和试剂；并向NIAID交付了2000剂cGMP原料药和2000剂cGMP最终候选容器。

The scope of product development activities that may be addressed through this award span manufacturing and formulation process development through clinical studies, including: manufacturing, characterization and release of pilot lot cGMP material; vaccine stability testing ; conduct of non-clinical studies, e.g., Investigational New Drug (IND)-enabling toxicology studies; development, qualification and, where necessary, validation of all assays and reagents needed to support product development; and the delivery to the NIAID of 2000 doses of cGMP bulk drug substance as well as 2000 doses of cGMP final container candidate.